Late Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complication

Persistent Link:
http://hdl.handle.net/10150/617198
Title:
Late Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complication
Author:
Yun, Seongseok ( 0000-0001-7343-1635 ) ; Vincelette, Nicole D.; Mansour, Iyad; Hariri, Dana; Motamed, Sara
Affiliation:
Department of Medicine, University of Arizona; Department of Pathology, University of Arizona
Issue Date:
2015
Publisher:
Hindawi
Citation:
Late Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complication 2015, 2015:1 Case Reports in Oncological Medicine
Journal:
Case Reports in Oncological Medicine
Rights:
Copyright © 2015 Seongseok Yun et al.This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Collection Information:
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.
Abstract:
Metastatic cutaneous melanoma has poor prognosis with 2-year survival rate of 10–20%. Melanoma cells express various antigens including gp100, melanoma antigen recognized by T cells 1 (MART-1), and tyrosinase, which can induce immune-mediated anticancer response via T cell activation. Cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) is an immune check point molecule that negatively regulates T cell activation and proliferation. Accordingly, recent phase III clinical trials demonstrated significant survival benefit with ipilimumab, a human monoclonal antibody (IgG1) that blocks the interaction of CTLA-4 with its ligands. Since the efficacy of ipilimumab depends on T cell activation, it is associated with substantial risk of immune mediated adverse reactions such as colitis, hepatitis, thyroiditis, and hypophysitis. We report the first case of late onset pericarditis and cardiac tamponade associated with ipilimumab treatment in patient with metastatic cutaneous melanoma.
Description:
UA Open Access Publishing Fund
Note:
Open access.
ISSN:
2090-6706; 2090-6714
DOI:
10.1155/2015/794842
Version:
Final published version
Additional Links:
http://www.hindawi.com/journals/crionm/2015/794842/

Full metadata record

DC FieldValue Language
dc.contributor.authorYun, Seongseoken
dc.contributor.authorVincelette, Nicole D.en
dc.contributor.authorMansour, Iyaden
dc.contributor.authorHariri, Danaen
dc.contributor.authorMotamed, Saraen
dc.date.accessioned2016-07-19T00:56:36Z-
dc.date.available2016-07-19T00:56:36Z-
dc.date.issued2015-
dc.identifier.citationLate Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complication 2015, 2015:1 Case Reports in Oncological Medicineen
dc.identifier.issn2090-6706-
dc.identifier.issn2090-6714-
dc.identifier.doi10.1155/2015/794842-
dc.identifier.urihttp://hdl.handle.net/10150/617198-
dc.descriptionUA Open Access Publishing Funden
dc.description.abstractMetastatic cutaneous melanoma has poor prognosis with 2-year survival rate of 10–20%. Melanoma cells express various antigens including gp100, melanoma antigen recognized by T cells 1 (MART-1), and tyrosinase, which can induce immune-mediated anticancer response via T cell activation. Cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) is an immune check point molecule that negatively regulates T cell activation and proliferation. Accordingly, recent phase III clinical trials demonstrated significant survival benefit with ipilimumab, a human monoclonal antibody (IgG1) that blocks the interaction of CTLA-4 with its ligands. Since the efficacy of ipilimumab depends on T cell activation, it is associated with substantial risk of immune mediated adverse reactions such as colitis, hepatitis, thyroiditis, and hypophysitis. We report the first case of late onset pericarditis and cardiac tamponade associated with ipilimumab treatment in patient with metastatic cutaneous melanoma.en
dc.language.isoenen
dc.publisherHindawien
dc.relation.urlhttp://www.hindawi.com/journals/crionm/2015/794842/en
dc.rightsCopyright © 2015 Seongseok Yun et al.This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.titleLate Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complicationen
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, University of Arizonaen
dc.contributor.departmentDepartment of Pathology, University of Arizonaen
dc.identifier.journalCase Reports in Oncological Medicineen
dc.description.noteOpen access.en
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en
dc.eprint.versionFinal published versionen
All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.